Changes in platelets after discontinuation of romiplostim

Some patients with immune thrombocytopenia (ITP) have platelet counts that remain unchanged after discontinuation of romiplostim. One trial studied platelet reactivity rates (≥50×109/L), response rates, splenectomy rates, and adverse events in patients with primary immune thrombocytopenia(ITP)duration ≤6 months who received romiplostim for ≤12 months. The starting dose of romiplostim is 1 μg/kg; concomitant and rescue therapy to maintain platelet counts is permitted. Patients with platelet counts ≥50 × 109/L at the end of 12 months enter a dose-tapering phase, in which the dose of romigrastim is reduced as long as the platelet count remains unchanged.

After stopping romiplostim, the patient's disease response (platelet count ≥50×109/L for 24 consecutive weeks without ITP treatment) was evaluated. High response rates (>90%) were observed within 12 months. Platelet responses occurred rapidly (median, approximately 2 weeks), and a cumulative median of 11 months was observed. Symptoms were relieved in 32% of patients; most patients began to feel relieved before mandatory tapering. No new safety signals were discovered. Therefore, in patients with early-stage ITP, romigrastim is well tolerated and induces a rapid response, with approximately one-third of patients experiencing remission.

RomiplostimThe original drug has been approved by the State Food and Drug Administration for marketing. Due to its short time on the market, it is not included in the scope of medical insurance. It may be difficult to purchase it domestically. The price of the original version in Hong Kong may be RMB 10,000 per pill (the price may fluctuate due to exchange rates). The price of the European version of romiplostim the original drug may be 11,000 RMB per pill, the German version may be 9,850 RMB per pill, and the Hong Kong version may be 8,900 RMB per pill (the price may fluctuate due to the exchange rate). The ingredients of the drugs are basically the same. For specific prices and drug details, please consult Yaode’s medical consultant.